Skip to Content Skip to Search

GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics

Issued: London, UK

GSK is committed to tackling antimicrobial resistance (AMR) as part of a sustained, multi-stakeholder response to this global health threat. As one of the few companies actively researching and developing new antibiotics to treat resistant infections, we welcome the UK Government’s long-term commitments to combating AMR. GSK believes that the UK Government commitment to test a new payment model to support antibiotics R&D has the potential to be game-changing and hopes that other countries will follow the UK’s lead. GSK also welcomes the recognition in the UK Government’s long-term plan of the key role that vaccines can play in reducing the need for antibiotics by preventing bacterial, viral and other infections.

Phil Thomson,

President, Global Affairs, GSK